NCT02514174 2020-03-30
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Boehringer Ingelheim
Phase 4 Completed
Clinical Trials
3 trialsNCT02208843 2018-12-17
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Boehringer Ingelheim
Phase 4 Completed
NCT02695290 2017-09-18
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Boehringer Ingelheim
Phase 4 Terminated